Curcumin Supplement in Nonalcoholic Fatty Liver Patients
NCT ID: NCT02908152
Last Updated: 2020-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
50 participants
INTERVENTIONAL
2017-02-10
2017-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Curcumin Supplementation and Patients With Type 2 Diabetes
NCT02529982
Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes
NCT02529969
Curcumin Supplementation for the Improvement of Diabetes-related Outcomes
NCT06984640
Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance
NCT01052025
The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes
NCT02929901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
curcumin
curcumin
curcumin
1500 mg
1 capsule / day for 12 weeks
placebo
placebo
1500 mg
1 capsule / day for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
curcumin
1500 mg
1 capsule / day for 12 weeks
placebo
1500 mg
1 capsule / day for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CAP score \>263.
Exclusion Criteria
* History of alcohol consumption;
* pregnancy or lactation;
* Professional athletes;
* Other liver disease (viral/etc);
* High dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine, immunosuppressive drugs;
* A history of Cardiovascular disease;
* Renal disease, Celiac disease, Cirrhosis;
* History of Upper GI surgery;
* A history of hypothyroidism or Cushing's syndrome;
* History of drug dependence;
* Body mass index (BMI) ≥35 kg/m2;
* A restrictive diet or weight change ≥ 5 kg during the 3months prior to study;
* Any change in treatment with oral hypoglycemic; anti hypertensive and antilipid agents during the study;
* Use of weight loss medications.
30 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Nutrition and Food Technology Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Azita Hekmatdoost
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NNFTRI
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
467
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.